Ervogastat | DGAT2 inhibitor

Ervogastat chemical structure

Available Options

Size:PriceQuantity 
5 mg$100.00
25 mg$395.00
Request Quote / Bulk / Custom Size
Product Inquiry

Ervogastat (2186700-33-2) is a potent (IC50 = 17.2 nM) and selective (against DGAT1 and MGATs 1-3) inhibitor of diacylglycerol transferase 2 (DGAT2). It reduced liver and plasma triglyceride levels in Sprague-Dawley rats feed a high fat high cholesterol diet by 49% and 70% respectively.1 Ervogastat displayed efficacy in combination with the ACC inhibitor clesacostat in resolving metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis.2

References/Citations:

  1. Futatsugi et al. (2022), Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis; J. Med. Chem. 65 15000
  2. Wong et al. (2025), Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomized, double-blind, double-dummy study; Lancet Gastroenterol. Hepatol. 10 924
2186700-33-2, DGAT2 inhibitor, Ergvogastat supplier, Ervogastat, PF-06865571, PF-06865571 supplier, selective DGAT2 inhibitor
Alternate Name:
PF-06865571

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Ervogastat (2186700-33-2) is a potent (IC50 = 17.2 nM) and selective (against DGAT1 and MGATs 1-3) inhibitor of diacylglycerol transferase 2 (DGAT2). It reduced liver and plasma triglyceride levels in Sprague-Dawley rats feed a high fat high cholesterol diet by 49% and 70% respectively.1 Ervogastat displayed efficacy in combination with the ACC inhibitor clesacostat in resolving metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis.2

References/Citations:

  1. Futatsugi et al. (2022), Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis; J. Med. Chem. 65 15000
  2. Wong et al. (2025), Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomized, double-blind, double-dummy study; Lancet Gastroenterol. Hepatol. 10 924